Veena Somayaji

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

Saswata Talukdar, Yingjiang Zhou, Dongmei Li et al. · Cell Metabolism · 2016 · 488 citations · Full text

Life Sciences, Biochemistry, Endocrinology +15

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Roberto A. Calle, Neeta B. Amin, Santos Carvajal‐Gonzalez et al. · Nature Medicine · 2021 · 219 citations

Medicine, Pharmacology, Pharmacotherapy +9

Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non‐human primates

Albert M. Kim, Veena Somayaji, Jennifer Dong et al. · Diabetes Obesity and Metabolism · 2017 · 139 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene

Michael R. McClung, Ethel S. Siris, Steve Cummings et al. · Menopause The Journal of The North American Menopause Society · 2006 · 110 citations

Medicine, Pharmacotherapy, Bone Metabolism +16

Pharmacokinetics and pharmacodynamics of PF‐05231023, a novel long‐acting FGF21 mimetic, in a first‐in‐human study

Jennifer Dong, Michelle I. Rossulek, Veena Somayaji et al. · British Journal of Clinical Pharmacology · 2015 · 98 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13